Core Insights - Group revenues decreased to € 535.1 million, reflecting a decline of 7.1% [1] - The Discovery & Preclinical Development segment experienced a significant drop of 12.3% due to soft demand [1] - Just - Evotec Biologics showed strong performance with an increase of 11.3%, exceeding expectations [1] - The company anticipates the advancement of up to four molecules into clinical phase II within the next six to nine months [1] - A landmark transaction with Sandoz was signed on November 4, potentially resulting in payments exceeding US$ 650 million plus royalties on a portfolio of up to 10 biosimilar molecules [1] - The company confirmed its guidance for 2025 and outlook for 2028 [1] Financial Performance - Group revenues reported at € 535.1 million, down 7.1% [1] - Discovery & Preclinical Development segment revenue declined by 12.3% [1] - Just - Evotec Biologics segment revenue increased by 11.3% [1] Strategic Developments - The market for early drug discovery services remains soft, but strategic partnerships are progressing well [1] - Strong advancements in the partnered asset pipeline are noted [1] - The company is on track with its systematic execution of strategy [1]